Servier, a global independent pharmaceutical group, has concluded its tender offer for Day One Biopharmaceuticals, acquiring all outstanding common stock at a price of $21.50 per share. This strategic move is designed to solidify Servier’s prominence in the low-grade glioma market and broaden its overall oncology footprint through the addition of specialized commercial products and a rare cancer pipeline.
A key highlight of the acquisition is the integration of OJEMDA™ (tovorafenib), an FDA-cleared therapy specifically for pediatric low-grade glioma, which represents the most frequent type of brain malignancy in children. The deal also encompasses Day One’s developmental assets, including the novel antibody-drug conjugate (ADC) Emi-Le (emiltatug ledadotin) and the targeted therapy project DAY301.
Servier’s leadership noted that integrating Day One’s scientific expertise and approved treatments will significantly enhance the group’s operational capacity in the United States. By combining resources, the organization aims to accelerate the delivery of innovative solutions for patients battling rare and life-threatening cancers, bridging the gap between laboratory innovation and clinical outcomes.
Source: https://www.contractpharma.com/breaking-news/servier-acquires-day-one-biopharmaceuticals/